ArticleJournal of cheminformatics2021
Comparison of structure- and ligand-based scoring functions for deep generative models: a GPCR case study.
Article in Journal of cheminformatics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 87 citations in OpenAlex.
- Novel molecular design via a scaffold-aware transformer with multi-scale attention mechanisms.Journal of cheminformatics · 2026Article
- Integrated Computer-Aided Drug Design: Advances in GPCR Natural Ligand Discovery.Cell biochemistry and biophysics · 2026Review
- Test-Time Training Scaling Laws for Chemical Exploration in Drug Design.Journal of chemical information and modeling · 2025Article
- REINFORCE-ING Chemical Language Models for Drug Discovery.Journal of chemical information and modeling · 2025Article
- Benchmarking 3D Structure-Based Molecule Generators.Journal of chemical information and modeling · 2025Article
- Identification of nanomolar adenosine ANature communications · 2025Article
- Activity cliff-aware reinforcement learning for de novo drug design.Journal of cheminformatics · 2025Article
- New strategies to enhance the efficiency and precision of drug discovery.Frontiers in pharmacology · 2025Review
- AI meets physics in computational structure-based drug discovery for GPCRs.npj drug discovery · 2025Review
- A systematic review of deep learning chemical language models in recent era.Journal of cheminformatics · 2024Review
- ACEGEN: Reinforcement Learning of Generative Chemical Agents for Drug Discovery.Journal of chemical information and modeling · 2024Article
- Diverse Hits in De Novo Molecule Design: Diversity-Based Comparison of Goal-Directed Generators.Journal of chemical information and modeling · 2024Article
- MolScore: a scoring, evaluation and benchmarking framework for generative models in de novo drug design.Journal of cheminformatics · 2024Article
- Development of scoring-assisted generative exploration (SAGE) and its application to dual inhibitor design for acetylcholinesterase and monoamine oxidase B.Journal of cheminformatics · 2024Article
- Comprehensive machine learning boosts structure-based virtual screening for PARP1 inhibitors.Journal of cheminformatics · 2024Article
- Directional ΔJournal of chemical information and modeling · 2024Article
- Decrypting orphan GPCR drug discovery via multitask learning.Journal of cheminformatics · 2024Article
- MAIP: An Open-Source Tool to Enrich High-Throughput Screening Output and Identify Novel, Druglike Molecules with Antimalarial Activity.ACS medicinal chemistry letters · 2023Article
- On the difficulty of validating molecular generative models realistically: a case study on public and proprietary data.Journal of cheminformatics · 2023Article
- Improving drug discovery with a hybrid deep generative model using reinforcement learning trained on a Bayesian docking approximation.Journal of computer-aided molecular design · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deep generative models have shown the ability to devise both valid and novel chemistry, which could significantly accelerate the identification of bioactive compounds. Many current models, however, use molecular descriptors or ligand-based predictive methods to guide molecule generation towards a desirable property space. This restricts their application to relatively data-rich targets, neglecting those where little data is available to sufficiently train a predictor. Moreover, ligand-based approaches often bias molecule generation towards previously established chemical space, thereby limiting their ability to identify truly novel chemotypes. In this work, we assess the ability of using molecular docking via Glide-a structure-based approach-as a scoring function to guide the deep generative model REINVENT and compare model performance and behaviour to a ligand-based scoring function. Additionally, we modify the previously published MOSES benchmarking dataset to remove any induced bias towards non-protonatable groups. We also propose a new metric to measure dataset diversity, which is less confounded by the distribution of heavy atom count than the commonly used internal diversity metric. With respect to the main findings, we found that when optimizing the docking score against DRD2, the model improves predicted ligand affinity beyond that of known DRD2 active molecules. In addition, generated molecules occupy complementary chemical and physicochemical space compared to the ligand-based approach, and novel physicochemical space compared to known DRD2 active molecules. Furthermore, the structure-based approach learns to generate molecules that satisfy crucial residue interactions, which is information only available when taking protein structure into account. Overall, this work demonstrates the advantage of using molecular docking to guide de novo molecule generation over ligand-based predictors with respect to predicted affinity, novelty, and the ability to identify key interactions between ligand and protein target. Practically, this approach has applications in early hit generation campaigns to enrich a virtual library towards a particular target, and also in novelty-focused projects, where de novo molecule generation either has no prior ligand knowledge available or should not be biased by it.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.